Antiretroviral/Anti HIV

DRUG2 trials

Conditions

Abnormality of Adipose TissueAntiviral Drug Adverse ReactionBody Fat DisorderBody Weight ChangesCardiovascular AbnormalitiesHIV-1-infectionHIV-Associated Lipodystrophy SyndromeVascular Diseases

Phase 4

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

CompletedNCT04340388

Augusta UniversityAbnormality of Adipose Tissue, Antiviral Drug Adverse Reaction, Body Fat Disorder +5

Start: 2020-09-17End: 2023-02-25Updated: 2023-07-27

Unknown Phase

ART First-line Treatment Durability in Russia

CompletedNCT04253119

MSD Pharmaceuticals LLCHIV-1-infection

Start: 2019-11-26End: 2022-06-30Updated: 2024-04-17

Antiretroviral/Anti HIV

Sponsors

Conditions

Phase 4

Unknown Phase